Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431489 | 0.89 | ALDH1A1 (0.32) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL3427278 | 0.89 | CSNK2A2 (0.41) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL3434049 | 0.89 | LPAR3 (0.37) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL14407788 | 0.84 | ALDH1A1 (0.41) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL3428966 | 0.84 | ALDH1A1 (0.41) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL16300835 | 0.84 | LPAR3 (0.39) | LPAR3LPAR2LPAR1HSD11B1 | |
| SCHEMBL7521230 | 0.83 | MAPT (0.45) | LPAR3LPAR2LPAR1CA12CA1 | |
| SCHEMBL22213099 | 0.82 | LPAR3 (0.47) | LPAR3LPAR2LPAR1S1PR1S1PR5 | |
| SCHEMBL10241147 | 0.82 | LPAR3 (0.42) | LPAR3LPAR2LPAR1 | |
| SCHEMBL3434052 | 0.81 | LMNA (0.40) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | LPAR3 3825/4885LPAR2 4113/4885LPAR1 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.